Extended use of bleeding control drugs after heart surgery
Part of Heart & circulation clinical trials.
This trial is for hospitals, not patients. Hospitals that do many open heart surgeries and whose doctors agree to use certain bleeding control drugs (fibrinolysis inhibitors) as per the study protocol can participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The hospital must perform at least 250 open heart surgeries each year.
- At least 95% of the doctors treating adult patients in the hospital must agree to follow the study's plan for using bleeding control drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what happens when a drug called fibrinogen (which helps blood clot) is paid for by insurance during complex heart surgeries. It aims to see if having this drug covered changes how much blood is needed or how long you stay in the hospital.
This trial tests a medicine called 4F-PCC to stop bleeding during complex heart surgery that uses a heart-lung machine. It could help people who have bleeding problems after the surgery.
This trial compares two treatments for bleeding after heart surgery: a medicine called FEIBA (which helps blood clot) and fresh frozen plasma (a blood product). The goal is to see which works better as a first treatment for bleeding during recovery.
This trial surveys surgeons about how they use hemostatic agents (medications that stop bleeding during surgery). It aims to understand current practices and improve patient safety.
This trial tests whether using a blood thinner in people with new, temporary atrial fibrillation after CABG (heart bypass surgery) can reduce harmful outcomes compared with standard treatment. It may help prevent stroke or other complications if your rhythm problem fits the trial’s timing and risk profile.
This study looks at how well blood thinners (anticoagulants) and inflammation markers work in people having heart or blood vessel procedures. It aims to better monitor these treatments to improve patient safety.
Hear when a new Thoracic Surgery trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.